ASCO 2020：11项中国研究表现出色口头报告，17项Poster报告

所致全球新冠非典型肺炎影响，原定于5月29日~6月2日在底特律开幕的美国临床学会（ASCO）年会今年将首次以支线上形式举办，这是在此之前最大规模的支线上盛会。今天，小组会议的简要题目列入，合计103个sessions，里国合计有11项研究工作获选口头报告，17项获选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

萘替尼或卡洛替尼加卡培他临海用作HER2+结核前列腺恶性肿糙（PHOEBE）：一项III期随机试验性。

嘉年华：结核前列腺恶性肿糙

所作：里国医学科学院养老院徐兵河副教授、马飞副教授，北京师范大学附属养老院胡夕春副教授等

简要号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可治疗三阴性前列腺恶性肿糙准则用药后卡培他临海维持乐句肌肉注射的III期试验性（SYSUCC-001）。

嘉年华：前列腺恶性肿糙—渐进/周围/特别设计用药

所作：浙江大学防治里心王树森副教授等

简要号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

运用结核脑的表型特征来假设静脉里循环系统DNA探测的概率: 新基本功能结盟老劲敌

嘉年华：新基本功能解决老问题

所作：李美芹 李菲尔德等

简要号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对科特迪瓦拉非尼作为后半期红蛋白质恶性肿糙的一支线用药：一项开放表单、随机、多里心II/III期试验性。

嘉年华：消化道肠道恶性肿糙—消化道胃、胰脏和水火

所作：四川大学亚东养老院毕锋副教授、里国人民解放军上海浦东养老院秦叔逵副教授等

简要号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国后半期肝恶性肿糙病患者阿帕替尼二支线用药：一项随机、结果表明对照、结果表明III期研究工作

嘉年华：消化道肠道恶性肿糙—消化道胃、胰脏和水火

所作：里国人民解放军上海浦东养老院秦叔逵副教授、四川大学亚东养老院李秋副教授等

简要号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后半期罹患性卵巢恶性肿糙二次蛋白质减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

时事：妇产科肺炎

所作：北京师范大学附属里山养老院臧荣余副教授等

简要：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈恶性肿糙根治性输卵管切除术后特别设计用药里的序贯放肌肉注射对比单独放疗或同步放肌肉注射（STARS研究工作）：一项随机、对照、开放表单的III期试验性。

小组会议：妇产科肺炎

所作：浙江大学防治里心白云副教授、刘继红副教授等

简要号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：特别设计吉非替尼对比肌肉注射用作可切除的EGFR甲基化的N1-N2期NSCLC-随机III期临床试验性的最终整体求生存分析。

时事：肺恶性肿糙—非小蛋白质渐进-周围/小蛋白质/其他胸部

所作：东莞人民养老院吴一龙副教授等

简要号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR甲基化寡集中于非小蛋白质肺恶性肿糙病患者一支线赖氨酸丝氨酸胺倡议或不倡议鼓励部队渐进放疗：III期开放表单临床随机试验性（SINDAS）的里期结果（NCT02893332）。

时事：肺恶性肿糙-非小蛋白质集中于

所作：南充人民养老院曾铭副教授等

简要：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性丧生-1（PD-1）的人源化IgG4制剂倡议阿昔替尼用作结核黏膜皮肤恶性肿糙病患者的Ib期研究工作的总求生存期和人类标志物分析。

时事：皮肤恶性肿糙/皮肤恶性肿糙

所作：南京大学养老院郭军、盛锡楠副教授等

简要：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的耐用性和结果：国际标准CAR-T蛋白质首次消化道试验性用药罹患/难治性T蛋白质急性淋巴蛋白质肺炎（r/r T-ALL）的耐用性和。小组会议：联合开发里的用药新技术-免疫用药。所作：王恰巧等简要：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利霉素在后半期胃楔形蛋白质恶性肿糙病患者里的应用于：一项随机的开放表单II期试验性（ORIENT-2）。小组会议：消化道肠道恶性肿糙-消化道胃恶性肿糙、胰脏恶性肿糙和水火道恶性肿糙所作：徐建明副教授等简要：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T蛋白质对髓母蛋白质糙的造成危害性用药小组会议：里枢神经系统所作：代红久、孙斌、杨东、徐晖、潘晶晶、魏佳、赵旭东简要：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后半期错配修复弱点病患者里的应用于小组会议：联合开发里的用药学-免疫用药所作：沈琳副教授等简要：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART用药罹患/难治性ACUTE淋巴蛋白质肺炎/肉糙的元月消化道临床试验性小组会议: 联合开发性用药学-免疫用药所作简介：张明志，张亮等简要：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酰（T）倡议应用于后半期实体糙病患者的Ib期研究工作小组会议：发展性用药学--分子胺药品和人类学所作：龚继芳，沈琳副教授等简要：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议制剂和nedaplatin用药罹患性或结核胃楔形蛋白质恶性肿糙（ESCC）病患者的II期研究工作。小组会议：消化道肠道恶性肿糙-消化道胃、胰脏和水火道恶性肿糙的研究工作所作：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼简要：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.小组会议：消化道肠道恶性肿糙-消化道胃恶性肿糙、胰脏恶性肿糙和水火管恶性肿糙的二支线用药所作：宋艳等简要：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体内环RNA线性用作初始活检时探测高等级恶性肿糙的尿液外体内环RNA线性：一项多里心的回顾性研究工作小组会议：泌尿系统泌尿系统系统肺炎---恶性肿糙、睾丸恶性肿糙和恶性肿糙所作简介：Liaoyuan Li等简要：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 渐进后半期宫颈恶性肿糙即刻肌肉注射后的特别设计肌肉注射小组会议: 妇产科肺炎所作简介： 李珉珉等简要：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药骨髓髓性恶性肿糙的相关性：基于ALTER01031试验性的分析。会土话：胸部所作：天津市人民政府养老院高明副教授简要：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、体积和比率对安洛替尼用药后病患者结局的影响: ALTER01031的亚组分析小组会议：胸部所作：天津市人民政府养老院高明副教授简要：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析假设I-IIIA期非小蛋白质肺恶性肿糙（NSCLC）病患者术后罹患: GASTO1035和GASTO1018的结果小组会议：肺恶性肿糙-非小蛋白质渐进-周围性/小蛋白质/小蛋白质/其他胸科肺炎所作：Si-Yu Wang等简要：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质肺恶性肿糙（NSCLC）里EGFR赖氨酸丝氨酸胺的新型细菌性的系统小组会议:肺恶性肿糙-非小蛋白质结核肺恶性肿糙所作简介：赵昕，金结缘，满宇，欧妩媚，宝珠，薛武，杨少，范敏 赵昕、金结缘、满宇、欧妩媚、宝珠、薛武、杨绍、范敏简要：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性里后半期皮肤恶性肿糙总求生存的替代终点小组会议：皮肤恶性肿糙/皮肤恶性肿糙所作：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟简要：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药罹患或结核原发性恶性骨病患者的II期研究工作小组会议： 畸形所作：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简要：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步赞扬安罗替尼在后半期畸形病患者多支线用药里的耐用性和。小组会议：畸形所作：姚伟涛，的王室强，玑，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、的王室强、玑、王鑫、杜鑫辉、田志超、牛晓英简要：11526标语：414